Clinical Trials Browser

Poly(ADP-ribose) Polymerase Inhibitors × Tumor-Agnostic × Clear all

NCT01311713 2024-01-30

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Phase 1/2 Terminated

45 enrolled 16 charts

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Neoplasms

NCT04326023 2021-03-11

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Neoplasms